Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L; CESAME Study Group.

Aliment Pharmacol Ther. 2017 Feb;45(4):533-541. doi: 10.1111/apt.13897. Epub 2016 Dec 19.

PMID:
27995656
2.

Mutations in DNAJB13, Encoding an HSP40 Family Member, Cause Primary Ciliary Dyskinesia and Male Infertility.

El Khouri E, Thomas L, Jeanson L, Bequignon E, Vallette B, Duquesnoy P, Montantin G, Copin B, Dastot-Le Moal F, Blanchon S, Papon JF, Lorès P, Yuan L, Collot N, Tissier S, Faucon C, Gacon G, Patrat C, Wolf JP, Dulioust E, Crestani B, Escudier E, Coste A, Legendre M, Touré A, Amselem S.

Am J Hum Genet. 2016 Aug 4;99(2):489-500. doi: 10.1016/j.ajhg.2016.06.022.

3.

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group.

Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9.

PMID:
26549003
4.
5.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group.

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.

PMID:
24162591
6.

RNF185 is a novel E3 ligase of endoplasmic reticulum-associated degradation (ERAD) that targets cystic fibrosis transmembrane conductance regulator (CFTR).

El Khouri E, Le Pavec G, Toledano MB, Delaunay-Moisan A.

J Biol Chem. 2013 Oct 25;288(43):31177-91. doi: 10.1074/jbc.M113.470500. Epub 2013 Sep 9.

7.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group.

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.

PMID:
22271569
8.

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group.

Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25.

PMID:
21708105
9.

Making sense of emergency surgery in New South Wales: a position statement.

Deane SA, MacLellan DG, Meredith GL, Cregan PC; Surgical Services Taskforce - Emergency Surgery Sub-group.

ANZ J Surg. 2010 Mar;80(3):139-44. doi: 10.1111/j.1445-2197.2010.05216.x.

PMID:
20575914
10.

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group.

Lancet. 2009 Nov 7;374(9701):1617-25. doi: 10.1016/S0140-6736(09)61302-7.

PMID:
19837455
11.

Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study.

Piton G, Cosnes J, Monnet E, Beaugerie L, Seksik P, Savoye G, Cadiot G, Flourie B, Capelle P, Marteau P, Lemann M, Colombel JF, Khouri E, Bonaz B, Carbonnel F.

Am J Gastroenterol. 2008 Jul;103(7):1730-6. doi: 10.1111/j.1572-0241.2008.01847.x. Epub 2008 Jun 28.

PMID:
18564124
12.

Cloning and characterisation of a gene from Plasmodium vivax and P. knowlesi: homology with valine-tRNA synthetase.

Snewin VA, Khouri E, Mattei D, Tekaia F, Delarue M, Mendis KN, David PH.

Gene. 1996 Sep 16;173(2):137-45.

PMID:
8964490
13.

A new polymorphic marker for PCR typing of Plasmodium vivax parasites.

Snewin VA, Khouri E, Wattavidanage J, Perera L, Premawansa S, Mendis KN, David PH.

Mol Biochem Parasitol. 1995 Apr;71(1):135-8. No abstract available.

PMID:
7630377
14.

Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector.

Snewin VA, Premawansa S, Kapilananda GM, Ratnayaka L, Udagama PV, Mattei DM, Khouri E, Del Giudice G, Peiris JS, Mendis KN, David PH.

J Exp Med. 1995 Jan 1;181(1):357-62.

15.

Plasmodium vivax:recombination between potential allelic types of the merozoite surface protein MSP1 in parasites isolated from patients.

Premawansa S, Snewin VA, Khouri E, Mendis KN, David PH.

Exp Parasitol. 1993 Mar;76(2):192-9.

PMID:
8454028
16.
17.

Plasmodium vivax: cloning and expression of a major blood-stage surface antigen.

del Portillo HA, Gysin J, Mattei DM, Khouri E, Udagama PV, Mendis KN, David PH.

Exp Parasitol. 1988 Dec;67(2):346-53.

PMID:
3056739
18.

Plasmodium vivax: karyotype polymorphism of field isolates.

Langsley G, Patarapotikul J, Handunnetti S, Khouri E, Mendis KN, David PH.

Exp Parasitol. 1988 Dec;67(2):301-6.

PMID:
3056737
19.

Coronary vasoactivity of adenosine in the conscious dog.

Olsson RA, Khouri EM, Bedynek JL Jr, McLean J.

Circ Res. 1979 Oct;45(4):468-78.

20.

Coronary vasoactivity of adenosine covalently linked to polylysine.

Olsson RA, Davis CC, Khouri EM.

Life Sci. 1977 Nov 1;21(9):1343-50. No abstract available.

PMID:
927034

Supplemental Content

Loading ...
Support Center